The agreement represents an early-stage investment in bispecific antibody technology, an emerging class of cancer treatments designed to target two biological markers simultaneously. The approach has attracted growing interest from major pharmaceutical companies seeking more precise therapies for patients with solid tumours.
Under the agreement, Disco will receive an initial payment of $40 million, alongside potential milestone payments of up to $2.5 billion. The biotechnology company will also be eligible for tiered royalties on worldwide net sales of products developed under the partnership.
The collaboration will focus on Disco's AND-gated bispecific therapeutics, which are designed to recognise cancer cells only when two target proteins are present simultaneously. By requiring both biological markers to be detected, the technology aims to improve treatment precision and potentially reduce damage to healthy tissue.
Disco will retain responsibility for research and discovery activities, while AbbVie will have exclusive licensing options over selected programmes for further development.
Disco Chief Executive Mark Manfredi said the partnership would allow the company to benefit from AbbVie's experience in target biology and pharmaceutical development.
The biotechnology company is already investigating AND-gated treatment approaches for small-cell lung cancer and colorectal cancer. Manfredi indicated that Disco expects to select a development candidate during the second half of 2027.
The agreement comes as pharmaceutical manufacturers increase investment in bispecific therapies, which have become an important area of research in oncology.
AbbVie has previously expanded its exposure to the technology through a January agreement with China's RemeGen, under which it paid $650 million upfront for rights outside China to a bispecific medicine targeting solid tumours.
Other pharmaceutical companies are also pursuing partnerships and acquisitions in the sector, reflecting growing competition to secure promising drug candidates before they reach advanced clinical development.
For AbbVie, the Disco agreement offers access to an emerging treatment platform that could strengthen its longer-term oncology pipeline. For the German biotechnology company, the partnership provides financial resources and access to an established pharmaceutical development partner.
However, the programme remains at an early research stage. No clinical development timetable has been disclosed, and future commercial returns will depend on research outcomes, licensing decisions, regulatory approval and eventual market adoption.






